Mingerlan (Tamsulosin Hydrochloride, Solifenacin Succinate)

Tamsulosin hydrochloride selectively blocks alpha‑1 adrenergic receptors in the smooth muscle of the prostate and bladder neck. This relaxation reduces resistance to urine flow, alleviating obstruction caused by an enlarged prostate and improving overall urinary symptoms.

The specific dose of Mingerlan is determined by the prescribing clinician based on the patient’s medical condition, age, renal and hepatic function, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for Mingerlan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Mingerlan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mingerlan combines an alpha‑1 blocker (tamsulosin) with a muscarinic antagonist (solifenacin), offering dual action on prostate smooth muscle and bladder detrusor activity. This contrasts with single‑agent therapies that target only one pathway, potentially providing broader symptom control for patients with both BPH and overactive bladder.

Mingerlan should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency.

Mingerlan is taken orally, usually once daily, with or without food as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include orthostatic hypotension leading to fainting, acute urinary retention, severe allergic reactions, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms such as sudden dizziness, inability to urinate, rash, swelling, or irregular heartbeat.

Mingerlan is contraindicated in patients with known hypersensitivity to tamsulosin, solifenacin, or any excipients in the formulation. It should also be avoided in individuals with severe hepatic impairment, uncontrolled narrow‑angle glaucoma, or those taking medications that may cause dangerous additive effects without proper monitoring.